Clinical trials: Obese Subjects
Type 2 Diabetes Mellitus
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy, safety, PK and PD characteristics of different doses of TG103 injection in overweight/obese subjects with type 2 diabetes mellitus.
- Trial name
- NCT05063253
- Testing
- TG103
- Volunteers
- 208 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Overweight and Obesity, Type2 Diabetes
A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerability, PK and PD of DD01 administered by…
- Conditions
- Overweight and Obesity, Type2 Diabetes, NAFLD
- Trial name
- NCT04812262
- Testing
- DD01
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 255 people
- Sponsor
- Neuraly, Inc.
Healthy Volunteer
A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)
Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral…
- Trial name
- NCT01018823
- Testing
- Ertugliflozin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Obesity and Overweight
Phase Ia Clinical Study of HDM1005 Injection
This is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase Ia clinical study. It is aimed to evaluate the safety, tolerability, PK and PD characteristics of HDM1005 injection in healthy adult…
- Trial name
- NCT06640647
- Where
- China
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Healthy Volunteer
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.
- Trial name
- NCT07414784
- Testing
- ABBV-295, Levonorgestrel/Ethinyl Estradiol
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbbVie
Obesity
Study for Short Term Weight Loss in Candidates for Bariatric Surgery
The purpose of this study is to determine whether the GI Endobarrier Liner is safe and effective.
- Trial name
- NCT00985491
- Testing
- Endobarrier Liner
- Where
- Chile
- Volunteers
- 46 people
- Sponsor
- Morphic Medical Inc.
Overweight/Obesity
Clinical Study of IBI362 in Healthy Chinese Male Subjects
This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.
- Trial name
- NCT04773977
- Testing
- IBI362 liquid formulation, IBI362 lyophilized powder
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity, Insulin Resistance
The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects
The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects.
- Trial name
- NCT00146289
- Testing
- MICARDIS® (telmisartan)
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 138 people
- Sponsor
- Boehringer Ingelheim
Obese Subjects With Polycystic Ovary Syndrome (PCOS)
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome
Randomized, double-blind, placebo-controlled study of HRS9531 in PCOS subjects
- Trial name
- NCT06595797
- Testing
- HRS9531
- Volunteers
- 144 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo).
- Trial name
- NCT04969939
- Testing
- Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
- Where
- 25 sites in United States
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine.
- Trial name
- NCT03842202
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687
This is a study in Japanese healthy volunteers to determine the safety and tolerability of the compound AZD7687. It will also assess how the body handles the drug and how it responds to the drug following single dose followed by…
- Trial name
- JSMAD (NCT01217905)
- Testing
- AZD7687
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat administered individually or combined three times per day for 24 weeks while on a reduced calorie diet (RCD) and also to evaluate the…
- Trial name
- NCT01126970
- Testing
- Velneperit 400 mg, Orlistat 120 mg, Reduced Calorie Diet
- Where
- 25 sites in United States
- Volunteers
- 486 people
- Sponsor
- Shionogi
Metabolism and Nutrition Disorder, Obesity
Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America (USA). The aim of this trial is to assess the safety and tolerability of single doses of NNC9204-1706 administered subcutaneously in male subjects being overweight or with…
- Trial name
- NCT03095807
- Testing
- NNC9204-1706 A
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obesity
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Overweight or Obese Male and Female Subjects.
- Trial name
- NCT04440345
- Testing
- IBI362
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight, Obesity
DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects
The main study objective is to evaluate the efficacy of IQP-AE-103 in reducing body weight in overweight and moderately obese subjects, in the context of an energy restricted diet.
- Trial name
- NCT04086797
- Testing
- IQP-AE-103
- Where
- Germany
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Perrigo CSCI
Obesity & Overweight
A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients
This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of VCT220 (other name: CX11) in subjects with moderate renal impairment compared with age-, sex-, and body mass index (BMI)-matched…
- Trial name
- NCT07347808
- Testing
- VCT220
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Overweight, Obese
The Study of [14C] GZR18
This trial is a Single-center, non-randomized, open-label, single-dose Mass Balance Study. The study period of each subject consists of a screening period (D-21 to D-2), a baseline period (D-2 to D-1), a dosing and routine…
- Conditions
- Overweight, Obese, Obesity
- Trial name
- NCT07119450
- Testing
- GZR18 injection、[14C]GZR18 injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Type II Diabetes Mellitus
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities.
- Trial name
- NCT07282743
- Testing
- GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3
- Where
- 21 sites in United States, India
- Volunteers
- 285 people
- Sponsor
- Sun Pharmaceutical Industries Limited